Moreover, RRM1 has been reported as a biomarker of treatment response in several neoplasms, such as MPM, non-small cell lung cancer and pancreatic adenocarcinoma; however, results from these studies are not conclusive about the role of RRM1 as a biomarker for treatment response in patients with MPM [11, 16, 18]. The gene discussed is RRM1; the disease is non-small cell lung carcinoma.